TG Therapeutics, Inc. $TGTX Shares Purchased by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management boosted its stake in TG Therapeutics by 1,278.8% in Q4, buying an additional 148,757 shares to hold 160,390 shares (about $4.78 million, ~0.10% of the company).
• Wall Street opinions are mixed but the MarketBeat consensus is a Moderate Buy with a $50 price target (1 Strong Buy, 3 Buy, 2 Hold), while recent price-target moves include Goldman Sachs to $39 and JPMorgan to $46.
• TGTX reported Q4 EPS $0.14 vs. estimates of $0.35 (a miss) while delivering $192.6 million in revenue, up 78% year-over-year; the stock trades near $31.75 with a market cap of about $5.07 billion.

Assenagon Asset Management S.A. increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1,278.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 160,390 shares of the biopharmaceutical company's stock after buying an additional 148,757 shares during the quarter. Assenagon Asset Management S.A. owned about 0.10% of TG Therapeutics worth $4,781,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in TGTX. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at $25,000. Danske Bank A S purchased a new stake in TG Therapeutics in the 3rd quarter valued at $25,000. Optiver Holding B.V. boosted its stake in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 732 shares during the period. Bessemer Group Inc. grew its position in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 486 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new position in TG Therapeutics during the 3rd quarter worth $34,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a "neutral" rating in a research note on Thursday, January 15th. Weiss Ratings reissued a "hold (c+)" rating on shares of TG Therapeutics in a report on Monday, December 29th. JPMorgan Chase & Co. dropped their price target on TG Therapeutics from $49.00 to $46.00 and set an "overweight" rating on the stock in a research report on Monday, February 2nd. Wall Street Zen downgraded TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $50.00.

TG Therapeutics Stock Down 0.7%

Shares of TG Therapeutics stock opened at $31.75 on Friday. TG Therapeutics, Inc. has a one year low of $25.28 and a one year high of $46.48. The company has a market cap of $5.07 billion, a P/E ratio of 11.46 and a beta of 1.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.29 and a current ratio of 4.10. The firm has a fifty day moving average of $29.76 and a two-hundred day moving average of $31.49.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.35 by ($0.21). The firm had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The company's revenue was up 78.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.15 earnings per share. On average, analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.